Cargando…

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine

No data regarding the efficacy of a third mRNA vaccine for solid cancer patients previously primed with the heterologous CoronoVac/ChAdOx1 vaccination implemented in Thailand during the shortage of vaccine supply are available. Forty-four cancer patients who previously received the heterologous Coro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luangdilok, Sutima, Wanchaijiraboon, Passakorn, Pakvisal, Nussara, Susiriwatananont, Thiti, Zungsontiporn, Nicha, Sriuranpong, Virote, Sainamthip, Panot, Suntronwong, Nungruthai, Vichaiwattana, Preeyaporn, Wanlapakorn, Nasamon, Poovorawan, Yong, Teeyapun, Nattaya, Tanasanvimon, Suebpong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608216/ https://www.ncbi.nlm.nih.gov/pubmed/36298478 http://dx.doi.org/10.3390/vaccines10101613

Ejemplares similares

Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment
por: Wanchaijiraboon, Passakorn, et al.
Publicado: (2022)

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
por: Wanchaijiraboon, Passakorn, et al.
Publicado: (2023)

Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls
por: Pakvisal, Nussara, et al.
Publicado: (2022)

Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study
por: Teeyapun, Nattaya, et al.
Publicado: (2022)

OP12 Durability and immunogenicity after two doses of ChAdOx1 nCov-19 among the type of cancer treatment in oncologic patients: A prospective, multicenter observational study
por: Wanchaijiraboon, P., et al.
Publicado: (2022)

Respiratory syncytial virus, human metapneumovirus, and influenza virus infection in Bangkok, 2016-2017
por: Thongpan, Ilada, et al.
Publicado: (2019)

Prevalence of antibodies against seasonal influenza A and B viruses among older adults in rural Thailand: A cross-sectional study
por: Suntronwong, Nungruthai, et al.
Publicado: (2021)

Effects of Complementary and Alternative Medicine on Chemotherapy Delivery in Thai Patients
por: Rabiltossaporn, Chawanya, et al.
Publicado: (2021)

Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study
por: Suntronwong, Nungruthai, et al.
Publicado: (2023)

Seroprevalence of Antibodies to Pertussis Toxin among Different Age Groups in Thailand after 37 Years of Universal Whole-Cell Pertussis Vaccination
por: Wanlapakorn, Nasamon, et al.
Publicado: (2016)

Antibodies to Bordetella pertussis antigens in maternal and cord blood pairs: a Thai cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2017)

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
por: Assawasaksakul, Theerada, et al.
Publicado: (2021)

Climate factors influence seasonal influenza activity in Bangkok, Thailand
por: Suntronwong, Nungruthai, et al.
Publicado: (2020)

Characterizing genetic and antigenic divergence from vaccine strain of influenza A and B viruses circulating in Thailand, 2017–2020
por: Suntronwong, Nungruthai, et al.
Publicado: (2021)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
por: Yorsaeng, Ritthideach, et al.
Publicado: (2022)

Safety and Immunogenicity of Homologous and Heterologous Adenoviral-Vectored and mRNA COVID-19 Vaccine Regimens in Radiotherapy Patients
por: Prayongrat, Anussara, et al.
Publicado: (2023)

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
por: Chansaenroj, Jira, et al.
Publicado: (2022)

Antibodies against measles and rubella virus among different age groups in Thailand: A population-based serological survey
por: Wanlapakorn, Nasamon, et al.
Publicado: (2019)

The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study
por: Archwamety, Anita, et al.
Publicado: (2022)

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
por: Assawasaksakul, Theerada, et al.
Publicado: (2022)

Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
por: Suntronwong, Nungruthai, et al.
Publicado: (2022)

Prognostic factors in completely resected lymph-node-negative pulmonary adenocarcinoma
por: Pakvisal, Nussara, et al.
Publicado: (2022)

COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
por: Suntronwong, Nungruthai, et al.
Publicado: (2022)

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
por: Assawakosri, Suvichada, et al.
Publicado: (2022)

SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis
por: Yorsaeng, Ritthideach, et al.
Publicado: (2023)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(TM)) after homologous and heterologous two-dose regimens
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Epidemiology and clinical characteristics of severe acute respiratory infections among hospitalized children under 5 years of age in a tertiary care center in Bangkok, Thailand, 2019–2020
por: Wanlapakorn, Nasamon, et al.
Publicado: (2023)

Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy
por: Navadurong, Huttakan, et al.
Publicado: (2023)

Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study
por: Assawasaksakul, Theerada, et al.
Publicado: (2022)

Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023
por: Chansaenroj, Jira, et al.
Publicado: (2023)

Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study
por: Charonpongsuntorn, Chanchai, et al.
Publicado: (2022)

Genetic and antigenic divergence in the influenza A(H3N2) virus circulating between 2016 and 2017 in Thailand
por: Suntronwong, Nungruthai, et al.
Publicado: (2017)

Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma
por: Pratedrat, Pornpitra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5fed7n84ruhao0pev2rn2dbm6g